{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:51:28Z","timestamp":1784170288177,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Research in Nagoya City University","award":["2313003"],"award-info":[{"award-number":["2313003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared survival outcomes of high-dose concomitant boost radiotherapy (HDCBRT) and conventional dose radiotherapy (CRT) for newly diagnosed glioblastoma (GB). Patients treated with intensity-modulated radiation therapy for newly diagnosed GB were included. In HDCBRT, specific targets received 69, 60, and 51\u00a0Gy in 30 fractions, while 60\u00a0Gy in 30 fractions was administered with a standard radiotherapy method in CRT. Overall survival (OS) and progression-free survival (PFS) were compared using the Log-rank test, followed by multivariate Cox analysis. The inverse probability of treatment weighting (IPTW) method was also applied to each analysis. Among 102 eligible patients, 45 received HDCBRT and 57 received CRT. With a median follow-up of 16\u00a0months, the median survival times of OS and PFS were 21 and 9\u00a0months, respectively. No significant differences were observed in OS or PFS in the Kaplan\u2013Meier analyses. In the multivariate analysis, HDCBRT correlated with improved OS (hazard ratio, 0.49; 95% confidence interval, 0.27\u20130.90; <jats:italic>P<\/jats:italic>\u2009=\u20090.021), and this result remained consistent after IPTW adjustments (<jats:italic>P<\/jats:italic>\u2009=\u20090.028). Conversely, dose suppression due to the proximity of normal tissues and IMRT field correlated with worse OS and PFS (<jats:italic>P<\/jats:italic>\u2009=\u20090.008 and 0.049, respectively). A prospective study with a stricter protocol is warranted to validate the efficacy of HDCBRT for GB.<\/jats:p>","DOI":"10.1038\/s41598-024-60154-y","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T06:02:16Z","timestamp":1713852136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Seiya","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-0119","authenticated-orcid":false,"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooru","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhito","family":"Mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Hiwatashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"60154_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330 (2005).","journal-title":"N. Engl. J. Med."},{"key":"60154_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","volume":"52","author":"CH Chang","year":"1983","unstructured":"Chang, C. H. et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer 52, 997\u20131007 (1983).","journal-title":"Cancer"},{"key":"60154_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","volume":"60","author":"L Souhami","year":"2004","unstructured":"Souhami, L. et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93\u201305 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60, 853\u2013860. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.04.011 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","volume":"97","author":"G Minniti","year":"2010","unstructured":"Minniti, G. et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother. Oncol. 97, 377\u2013381. https:\/\/doi.org\/10.1016\/j.radonc.2010.08.020 (2010).","journal-title":"Radiother. Oncol."},{"key":"60154_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7 (2009).","journal-title":"Lancet Oncol."},{"key":"60154_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.radonc.2010.08.018","volume":"97","author":"D Amelio","year":"2010","unstructured":"Amelio, D., Lorentini, S., Schwarz, M. & Amichetti, M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues. Radiother. Oncol. 97, 361\u2013369. https:\/\/doi.org\/10.1016\/j.radonc.2010.08.018 (2010).","journal-title":"Radiother. Oncol."},{"key":"60154_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ijrobp.2006.10.032","volume":"67","author":"U Hermanto","year":"2007","unstructured":"Hermanto, U. et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: Does IMRT increase the integral dose to normal brain?. Int. J. Radiat. Oncol. Biol. Phys. 67, 1135\u20131144. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.10.032 (2007).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13014-019-1305-1","volume":"14","author":"L Zhong","year":"2019","unstructured":"Zhong, L. et al. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Radiat. Oncol. 14, 104. https:\/\/doi.org\/10.1186\/s13014-019-1305-1 (2019).","journal-title":"Radiat. Oncol."},{"key":"60154_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-018-1194-8","volume":"13","author":"S Zschaeck","year":"2018","unstructured":"Zschaeck, S. et al. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. Radiat. Oncol. 13, 1\u20139. https:\/\/doi.org\/10.1186\/s13014-018-1194-8 (2018).","journal-title":"Radiat. Oncol."},{"key":"60154_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s11060-018-2831-7","volume":"138","author":"T Wakabayashi","year":"2018","unstructured":"Wakabayashi, T. et al. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon\u03b2 plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J. Neurooncol. 138, 627\u2013636. https:\/\/doi.org\/10.1007\/s11060-018-2831-7 (2018).","journal-title":"J. Neurooncol."},{"key":"60154_CR11","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963\u20131972. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541 (2010).","journal-title":"J. Clin. Oncol."},{"key":"60154_CR12","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34, 3661\u20133679. https:\/\/doi.org\/10.1002\/sim.6607 (2015).","journal-title":"Stat. Med."},{"key":"60154_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","volume":"81","author":"J Li","year":"2011","unstructured":"Li, J. et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 81, 623\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.012 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11060-018-2932-3","volume":"140","author":"S Mallick","year":"2018","unstructured":"Mallick, S. et al. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial). J. Neurooncol. 140, 75\u201382. https:\/\/doi.org\/10.1007\/s11060-018-2932-3 (2018).","journal-title":"J. Neurooncol."},{"key":"60154_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ijrobp.2009.08.029","volume":"78","author":"KH Cho","year":"2010","unstructured":"Cho, K. H. et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 78, 390\u2013397. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.029 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-023-04391-7","volume":"164","author":"S Mallick","year":"2023","unstructured":"Mallick, S. et al. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial. J. Neurooncol. 164, 141\u2013146. https:\/\/doi.org\/10.1007\/s11060-023-04391-7 (2023).","journal-title":"J. Neurooncol."},{"key":"60154_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00066-014-0638-9","volume":"190","author":"P Pedicini","year":"2014","unstructured":"Pedicini, P. et al. Clinical radiobiology of glioblastoma multiforme: Estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlentherapie und Onkol. 190, 925\u2013932. https:\/\/doi.org\/10.1007\/s00066-014-0638-9 (2014).","journal-title":"Strahlentherapie und Onkol."},{"key":"60154_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijrobp.2006.12.025","volume":"68","author":"B Jones","year":"2007","unstructured":"Jones, B. & Sanghera, P. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 68, 441\u2013448. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.12.025 (2007).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(05)70395-8","volume":"6","author":"M Tanaka","year":"2005","unstructured":"Tanaka, M., Ino, Y., Nakagawa, K., Tago, M. & Todo, T. High-dose conformal radiotherapy for supratentorial malignant glioma: A historical comparison. Lancet Oncol. 6, 953\u2013960. https:\/\/doi.org\/10.1016\/S1470-2045(05)70395-8 (2005).","journal-title":"Lancet Oncol."},{"key":"60154_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2014.07.014","volume":"90","author":"SN Badiyan","year":"2014","unstructured":"Badiyan, S. N. et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int. J. Radiat. Oncol. Biol. Phys. 90, 877\u2013885. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.07.014 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0360-3016(90)90534-q","volume":"19","author":"PJ Miller","year":"1990","unstructured":"Miller, P. J. et al. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 19, 275\u201380. https:\/\/doi.org\/10.1016\/0360-3016(90)90534-q (1990).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0233188","volume":"15","author":"LT Shieh","year":"2020","unstructured":"Shieh, L. T. et al. Survival of glioblastoma treated with a moderately escalated radiation dose\u2014Results of a retrospective analysis. PLoS One 15, 1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0233188 (2020).","journal-title":"PLoS One"},{"key":"60154_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","volume":"143","author":"TJ Kruser","year":"2019","unstructured":"Kruser, T. J. et al. NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J. Neurooncol. 143, 157\u2013166. https:\/\/doi.org\/10.1007\/s11060-019-03152-9 (2019).","journal-title":"J. Neurooncol."},{"key":"60154_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.30.9.907","volume":"30","author":"FH Hochberg","year":"1980","unstructured":"Hochberg, F. H. & Pruitt, A. Assumptions in the radiotherapy of glioblastoma. Neurology 30, 907\u2013911. https:\/\/doi.org\/10.1212\/wnl.30.9.907 (1980).","journal-title":"Neurology"},{"key":"60154_CR25","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J. Clin. Oncol. 31, 4085\u20134091. https:\/\/doi.org\/10.1200\/JCO.2013.49.6968 (2013).","journal-title":"J. Clin. Oncol."},{"key":"60154_CR26","doi-asserted-by":"crossref","unstructured":"Paulsson, A. K. et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am. J. Clin. Oncol. Cancer Clin. Trials 37, 177\u2013181 (2014)","DOI":"10.1097\/COC.0b013e318271ae03"},{"key":"60154_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.radonc.2019.12.005","volume":"145","author":"DF Fleischmann","year":"2020","unstructured":"Fleischmann, D. F. et al. Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? \u2013 A recurrence pattern analysis. Radiother. Oncol. 145, 49\u201355. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.005 (2020).","journal-title":"Radiother. Oncol."},{"key":"60154_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","volume":"110","author":"NN Laack","year":"2021","unstructured":"Laack, N. N. et al. Initial results of a phase 2 trial of 18F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 110, 1383\u20131395. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.032 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"60154_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-019-03166-3","volume":"143","author":"MM Kim","year":"2019","unstructured":"Kim, M. M. et al. Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. J. Neurooncol. 143, 313\u2013319. https:\/\/doi.org\/10.1007\/s11060-019-03166-3 (2019).","journal-title":"J. Neurooncol."},{"key":"60154_CR30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","volume":"139","author":"KL Pitter","year":"2016","unstructured":"Pitter, K. L. et al. Corticosteroids compromise survival in glioblastoma. Brain 139, 1458\u20131471. https:\/\/doi.org\/10.1093\/brain\/aww046 (2016).","journal-title":"Brain"},{"key":"60154_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11060-017-2562-1","volume":"135","author":"A-W Awad","year":"2017","unstructured":"Awad, A.-W. et al. Impact of removed tumor volume and location on patient outcome in glioblastoma. J. Neurooncol. 135, 161\u2013171. https:\/\/doi.org\/10.1007\/s11060-017-2562-1 (2017).","journal-title":"J. Neurooncol."},{"key":"60154_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2017.02.014","volume":"123","author":"CW Wee","year":"2017","unstructured":"Wee, C. W. et al. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother. Oncol. 123, 106\u2013111. https:\/\/doi.org\/10.1016\/j.radonc.2017.02.014 (2017).","journal-title":"Radiother. Oncol."},{"key":"60154_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes, A. A. et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status. J. Clin. Oncol. 27, 1275\u20131279. https:\/\/doi.org\/10.1200\/JCO.2008.19.4969 (2009).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60154-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T06:05:40Z","timestamp":1713852340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60154-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["60154"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-60154-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9283"}}